MaaT Pharma (EURONEXT: MAAT – the “Company”), an advanced clinical stage biotechnology company, leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving the survival of cancer patients, informs its shareholders that its General Meeting mixed (ordinary and extraordinary) will take place on May 28, 2024 at 11:00 a.m. CET at its head office in France, located at 70 avenue Tony Garnier, 69007 Lyon.
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]